DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Building on these complexities, therapeutic targeting of dystrophin deficiency faces challenges, including the need to reach large muscle masses (both skeletal and cardiac), the extreme size of the DMD gene (2.3 Mb, 11 kb cDNA, 79 exons) (Figure 1) and extensive genetic variability.